300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Restaurants
Crowdfunding
Financial Services
Hospitality
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Poland
Oman
Puerto Rico
Colombia
Guernsey
Cameroon
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
New Zealand
Seychelles
Moldova
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Bangladesh
Angola
Europe
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bahamas
Bahrain
Jersey
Estonia
Bulgaria
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Grenada
Hungary
Honduras
Israel
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
WuXi Biologics, VC Fund

WuXi Biologics

VC Fund

Wuxi, China

WuXi Biologics is a open-access technology platform company offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. Across the global biologics research and development community, we enable our partners to find innovative biological treatments for diseasesworldwide.

Total investments:
8
Last investment:
Lead investor:
0%

Last updated:

Industries WuXi Biologics invests in

BiotechnologyBiopharmaMedicalHealth CareTherapeutics

Stages WuXi Biologics invests in

Series ASeries BSeedConvertible Note

Countries WuXi Biologics invests in

ChinaUnited States

Contacts

NameEmailPhoneSocials
Shaymaa Taieb Shaymaa Taieb
Chris Chen
Christine Lu-Wong
Weichang Zhou
Zhisheng Chen

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Biotechnology 6 (75%)
  • Biopharma 4 (50%)
  • Medical 3 (38%)
  • Health Care 3 (38%)
  • Therapeutics 3 (38%)
See all 8 industries →

Stage

  • Series A 3 (38%)
  • Series B 2 (25%)
  • Seed 1 (13%)
  • Convertible Note 1 (13%)

Country

  • China 3 (38%)
  • United States 3 (38%)

Team

NameTitleInvestmentsLinksEmail
Shaymaa Taieb
Shaymaa Taieb Associate Director, upstream Continious Manufacturing
Associate Director, upstream Continious Manufacturing Total investments: 0
Find email
Chris Chen Chief Executive Officer
Chief Executive Officer Total investments: 2 Find email
Christine Lu-Wong Chief Financial Officer & Executive Vice President
Chief Financial Officer & Executive Vice President Total investments: 0 Find email
Weichang Zhou Chief Technology Officer & Executive Vice President
Chief Technology Officer & Executive Vice President Total investments: 0 Find email
Zhisheng Chen Chief Executive Officer
Chief Executive Officer Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
Innolake Biopharm Innolake Biopharm
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas. $14.1M / Series A / Jun 05, 2023
Duality Biologics Duality Biologics
“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company hasbuilt a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development. $90M / Series B / May 19, 2021
Immune-Onc Therapeutics Immune-Onc Therapeutics
Immune-Onc Therapeutics is a newly established bio-pharmaceutical company that focuses on developing innovative therapeutic antibodies for cancer treatment. The company applies the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients. $73M / Series B / Mar 30, 2021
Innolake Biopharm Innolake Biopharm
Innolake Biopharm clinical-stage biotech company with a focus on oncology and autoimmune disease areas. $45.9M / Seed / Jan 01, 2021
Invetx Invetx
Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. $10.3M / Series A / Sep 30, 2020
Invetx Invetx
Invetx is a veterinary therapeutics company that focuses on biopharmaceuticals that bring human biotechnology to animal health.Invetx is building the world’s premier animal health biotechnology innovation platform for protein-based therapeutics.Working closely with best-in-class biotechnology companies, major investors and an extensive networkof industry experts, Invetx is focused on guiding the development of an exciting portfolio of therapies and technologies to deliver the future of animal care.Invetx's network includes experts in both animal and human health, veterinary scientists and clinicians. The company's vision is of a global animal health industry that fully leverages biopharma technologies to deliver dramatically improved health outcomes for pets and farm animal populations. $15M / Series A / Feb 24, 2020
Inhibrx Inhibrx
Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology,orphan diseases, and infectious diseases. Inhibrx has collaborations with Celgene and Bluebird Bio and has received awards from several granting agencies, including NIH, NIAID, and CARB-X. $40M / Convertible Note / May 21, 2019
Duoning Biotech Duoning Biotech
Duoning Biotech is a serum-free medium and technology developer based on international animal cell culture concepts and process development experience. It is committed to the development and production of serum-free media for new animal cells, while providing formula production and technical support for the biopharmaceutical industry. Withancillary services, the products include basic media such as S1, S2, S3, S3-CD and S4, as well as 2×103 feeds and other feed media based on 2×103 feeds; and customized services. $14.2M / Series A / Apr 23, 2019

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Restaurants
Crowdfunding
Financial Services
Hospitality
Construction
Mobile
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Oil and Gas
Film
Retail
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Social Network
B2B
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Faroe Islands
South Korea
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Poland
Oman
Puerto Rico
Colombia
Guernsey
Cameroon
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Morocco
Australia
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
New Zealand
Seychelles
Moldova
Botswana
Paraguay
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Bangladesh
Angola
Europe
Cyprus
Qatar
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bahamas
Bahrain
Jersey
Estonia
Bulgaria
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Grenada
Hungary
Honduras
Israel
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does WuXi Biologics invest in?

WuXi Biologics invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact WuXi Biologics?

Public channels for WuXi Biologics include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at WuXi Biologics?

The team at WuXi Biologics includes Shaymaa Taieb (Associate Director, upstream Continious Manufacturing), Chris Chen (Chief Executive Officer) and Christine Lu-Wong (Chief Financial Officer & Executive Vice President). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
WuXi Biologics WuXi Biologics Find emails